Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Nanosuspension for parenteral delivery of a p-terphenyl derivative: preparation, characteristics and pharmacokinetic studies.

Tian X, Li H, Zhang D, Liu G, Jia L, Zheng D, Shen J, Shen Y, Zhang Q.

Colloids Surf B Biointerfaces. 2013 Aug 1;108:29-33. doi: 10.1016/j.colsurfb.2013.02.038.

PMID:
23528604
2.

Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.

Li W, Yang Y, Tian Y, Xu X, Chen Y, Mu L, Zhang Y, Fang L.

Int J Pharm. 2011 Apr 15;408(1-2):157-62. doi: 10.1016/j.ijpharm.2011.01.059.

PMID:
21295124
3.

Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.

Guo JJ, Yue PF, Lv JL, Han J, Fu SS, Jin SX, Jin SY, Yuan HL.

Int J Pharm. 2013 Jan 30;441(1-2):227-33. doi: 10.1016/j.ijpharm.2012.11.039.

PMID:
23220096
4.

Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.

Miao X, Sun C, Jiang T, Zheng L, Wang T, Wang S.

J Pharm Pharm Sci. 2011;14(2):196-214.

5.

Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.

Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, Cui F.

Eur J Pharm Sci. 2010 Jul 11;40(4):325-34. doi: 10.1016/j.ejps.2010.04.006.

PMID:
20417274
6.

Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies.

Zhang D, Tan T, Gao L, Zhao W, Wang P.

Drug Dev Ind Pharm. 2007 May;33(5):569-75.

PMID:
17520449
7.

Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation.

Yadav SK, Mishra S, Mishra B.

AAPS PharmSciTech. 2012 Dec;13(4):1031-44. doi: 10.1208/s12249-012-9833-0.

8.

Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery.

Wang Y, Li X, Wang L, Xu Y, Cheng X, Wei P.

Int J Nanomedicine. 2011;6:1497-507. doi: 10.2147/IJN.S21097.

9.

Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions.

Li W, Quan P, Zhang Y, Cheng J, Liu J, Cun D, Xiang R, Fang L.

Int J Pharm. 2014 Jan 2;460(1-2):13-23. doi: 10.1016/j.ijpharm.2013.10.038.

PMID:
24184036
10.

Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability.

Liu D, Xu H, Tian B, Yuan K, Pan H, Ma S, Yang X, Pan W.

AAPS PharmSciTech. 2012 Mar;13(1):295-304. doi: 10.1208/s12249-011-9750-7.

11.

Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders.

Du B, Li XT, Zhao Y, A YM, Zhang ZZ.

Pharmazie. 2010 Jul;65(7):471-6.

PMID:
20662313
12.

Development and characterization of an orodispersible film containing drug nanoparticles.

Shen BD, Shen CY, Yuan XD, Bai JX, Lv QY, Xu H, Dai L, Yu C, Han J, Yuan HL.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1348-56. doi: 10.1016/j.ejpb.2013.09.019.

PMID:
24103635
13.

Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.

Wang Y, Liu Z, Zhang D, Gao X, Zhang X, Duan C, Jia L, Feng F, Huang Y, Shen Y, Zhang Q.

Colloids Surf B Biointerfaces. 2011 Apr 1;83(2):189-97. doi: 10.1016/j.colsurfb.2010.10.029.

PMID:
21176876
14.

Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.

Hong C, Dang Y, Lin G, Yao Y, Li G, Ji G, Shen H, Xie Y.

Int J Pharm. 2014 Dec 30;477(1-2):251-60. doi: 10.1016/j.ijpharm.2014.10.044.

PMID:
25445518
15.

Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.

Ige PP, Baria RK, Gattani SG.

Colloids Surf B Biointerfaces. 2013 Aug 1;108:366-73. doi: 10.1016/j.colsurfb.2013.02.043.

PMID:
23602990
16.
17.

Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery.

Liu Y, Zhang D, Duan C, Jia L, Xie P, Zheng D, Wang F, Liu G, Hao L, Zhang X, Zhang Q.

J Microencapsul. 2012;29(2):194-203. doi: 10.3109/02652048.2011.642015.

PMID:
22172025
18.

Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement.

Gao L, Zhang D, Chen M, Zheng T, Wang S.

Drug Dev Ind Pharm. 2007 Dec;33(12):1332-9.

PMID:
18097807
19.

Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.

Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda AM.

Int J Pharm. 2009 May 21;373(1-2):124-32. doi: 10.1016/j.ijpharm.2009.01.024.

PMID:
19429297
20.

Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.

Pu X, Sun J, Wang Y, Wang Y, Liu X, Zhang P, Tang X, Pan W, Han J, He Z.

Int J Pharm. 2009 Sep 8;379(1):167-73. doi: 10.1016/j.ijpharm.2009.05.062.

PMID:
19505545
Items per page

Supplemental Content

Support Center